- Home
- MLTX vs GHRS Comparison
MLTX vs GHRS Comparison
Compare MLTX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | GHRS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | Switzerland | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.7M | 892.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MLTX | GHRS |
|---|---|---|
| Price | $14.59 | $14.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $36.33 | $30.11 |
| AVG Volume (30 Days) | ★ 2.0M | 328.2K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $6.72 |
| 52 Week High | $62.75 | $20.50 |
Technical Indicators
Market Signals| Indicator | MLTX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 50.88 |
| Support Level | $12.48 | $13.94 |
| Resistance Level | $15.56 | $15.86 |
| Average True Range (ATR) | 0.78 | 0.79 |
| MACD | 0.46 | -0.01 |
| Stochastic Oscillator | 69.76 | 31.16 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.